Yuhan/Viromed jointly to develop therapy for chronic granulomas.

Yuhan signed an agreement with Viromed Inc., a biotech company of Korea, at the head office on Jan. 18 for a joint research and development of a gene therapeutic compound VM106 for the treatment of chronic granulomas, a hereditary immune deficiency disease.

Two parties by this joint agreement committed a technology share at reciprocal advantages with the gene therapeutic technologies of Viro...